Idiopathic Pulmonary Fibrosis (IPF) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Idiopathic Pulmonary Fibrosis (IPF) Market Outlook

Thelansis's "Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Pulmonary Fibrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Idiopathic Pulmonary Fibrosis (IPF) Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology, characterized by irreversible fibrosis of lung parenchyma and a usual interstitial pneumonia (UIP) pattern on high-resolution CT or histopathology. It primarily affects adults over the age of 60 and is one of the most severe forms of idiopathic interstitial pneumonias.

Clinically, IPF presents with progressive exertional dyspnea and persistent dry cough, along with characteristic "Velcro-like" inspiratory crackles on auscultation. The disease is marked by ongoing epithelial injury, aberrant wound healing, and excessive fibrotic deposition, leading to declining lung function and impaired gas exchange.

IPF follows a relentlessly progressive course, often punctuated by acute exacerbations, and is associated with poor prognosis and reduced survival. While antifibrotic therapies (e.g., pirfenidone and nintedanib) can slow disease progression, they do not reverse fibrosis, and lung transplantation remains the only definitive treatment in eligible patients.

Key Highlights

• IPF is a progressive, high-mortality fibrotic lung disease with limited therapeutic options
• UK diagnosed prevalence expected to increase from ~38.7K to ~49.1K (~2.4% CAGR)

Market Overview

• Germany market projected to grow from ~$210M to ~$415M (~7% CAGR)
• Growth driven by antifibrotic therapies and improved diagnosis, with ongoing unmet need for curative treatments

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• PureTech
• AbbVie
• Mediar Therapeutics
• Tvardi Therapeutics, Incorporated
• Contineum Therapeutics
• Calluna Pharma AS
• Haisco Pharmaceutical Group Co., Ltd.
• Boehringer Ingelheim
• Syndax Pharmaceuticals
• Cumberland Pharmaceuticals
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Bristol-Myers Squibb
• Arrowhead Pharmaceuticals
• Rein Therapeutics
• Regend Therapeutics
• Trevi Therapeutics
• Vicore Pharma AB
• Actelion
• Daewoong Pharmaceutical Co. LTD.
• Overseas Pharmaceuticals, Ltd.
• Pliant Therapeutics, Inc.
• Chiesi Farmaceutici S.p.A.
• Bridge Biotherapeutics, Inc.
• GlaxoSmithKline
• HuniLife Biotechnology, Inc.
• Endeavor Biomedicines, Inc.
• siRNAgen Therapeutics Inc.
• Genosco Inc.
• SPARK Biopharma
• Dragonboat Biopharmaceutical Company Limited
• Mannkind Corporation
• Beijing Tide Pharmaceutical Co., Ltd
• Shanghai Synvida Biotechnology Co.,Ltd.
• Guangdong Raynovent Biotech Co., Ltd
• Avalyn Pharma Inc.
• InSilico Medicine Hong Kong Limited
• MediciNova
• GRI Bio Operations, Inc.
• Nerre Therapeutics Ltd.
• Sunshine Lake Pharma Co., Ltd.
• United Therapeutics
• Melius Pharma AB
• Pulmongene Ltd.
• Agomab Spain S.L.